CALDERA PHARMACEUTICALS, INC.

Basic Information

278 DP Road Suite D
LOS ALAMOS, NM, 87544-3334

Company Profile

n/a

Additional Details

Field Value
DUNS: 147452275
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 12


  1. XRpro Radioactive Cesium Decorporation Agents

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): Caldera aims to develop an inexpensive, stable, selective, decorporation (decorp) agent for cesium-137 (Cs-137). Cs-137 is easily obtainable by terrorists and trea ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Selective Decorporation Agents for NIAID

    Amount: $3,000,000.00

    DESCRIPTION (provided by applicant): This Phase II project continues the successful Phase I discovery of novel decorporation agents that are selective for radioactive strontium (Sr). This project cons ...

    SBIR Phase II 2011 Department of Health and Human Services
  3. Probes for Transient Kinase Complexes

    Amount: $98,917.00

    DESCRIPTION (provided by applicant): Most cellular processes are regulated by reversible protein phosphorylation, which is controlled by protein kinases and phosphatases. Caldera Pharmaceuticals and M ...

    SBIR Phase I 2010 Department of Health and Human Services
  4. XRpro Technology for the Detection and Evaluation of Carcinogens

    Amount: $200,000.00

    DESCRIPTION (provided by applicant): Caldera Pharmaceuticals will develop quantitative biomarker assays for a set of carcinogens. In Phase I, Caldera will demonstrate the feasibility of using its nove ...

    SBIR Phase I 2010 Department of Health and Human Services
  5. XRpro Discovery of Decorporation Agents

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): Caldera Pharmaceuticals will use award-winning XRpro, a high throughput, label-free technology for producing nano-engineered radionuclide decorporation agents that ...

    SBIR Phase I 2009 Department of Health and Human Services
  6. Iron Man: Novel Technologies for Autonomous Defense

    Amount: $100,000.00

    Caldera Pharmaceuticals proposes to develop a highly metal-selective system to maintain iron concentrations in the body at optimal levels to prevent infections. The system will control iron without th ...

    STTR Phase I 2009 Defense Advanced Research Projects AgencyDepartment of DefenseDepartment of Defense
  7. Innovative technologies to effectively treat multi-drug resistant and/or biofilm-embedded bacteria

    Amount: $100,000.00

    Antibiotic resistance is a major concern for both military and civilian populations. The US FDA reports that about 70 percent of bacteria that cause infections in hospitals are resistant to at least o ...

    STTR Phase I 2009 Defense Advanced Research Projects AgencyDepartment of DefenseDepartment of Defense
  8. Biomolecular Taggants for Covert Tracking and Watermarking

    Amount: $736,289.00

    Functional taggants are paints or inks that change their optical properties in response to specified environmental conditions, such as the presence of a chemical related to illicit weapon activities. ...

    SBIR Phase II 2009 Air ForceDepartment of DefenseDepartment of Defense
  9. Biomolecular Taggants for Covert Tracking and Watermarking

    Amount: $100,000.00

    Caldera will use its R&D 100 award-winning XRpro technologyto develop functional biomolecular taggants for Chemical/Biological/Radiological/Nuclear/Explosive (CBRNE) targets. These taggants will poss ...

    SBIR Phase I 2008 Air ForceDepartment of DefenseDepartment of Defense
  10. Novel Micro-X-ray Translucent Flow Cell Technology for Proteomics, a Broadly Appl

    Amount: $400,000.00

    DESCRIPTION (provided by applicant): Caldera Pharmaceutical's aim is to develop a broadly applicable, quantitative research tool which addresses core technical challenges in the field of proteomics, i ...

    SBIR Phase I 2007 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government